Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 18 U.S.C. §208(b)(3)

David Harrington, Ph.D.

Committee: **Oncologic Drugs Advisory Committee**

Meeting Date: May 9, 2007

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to New Drug Application Junovan (mifamurtide), formerly known as (L-MTP-PE, liposomal muramy tripeptide phosphatidyl ethanolamine), sponsored by IDM Pharma, Inc., for treatment of high-grade resectable non-metastatic osteosarcoma in combination with adjuvant chemotherapy for osteosarcoma. Genzyme Corporation, NOF Corporation, Ben Venue Laboratories, owned by Boehringer Ingelheim Corporation, the U.S. affiliate of Boehringer Ingelheim GmbH, and Solvias AG are the contract manufacturers of the liposomal formulation of muramyl tripeptide phosphatidylethanolamine. I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Unrelated Data Safety Monitoring Committee	Competitor	Less than \$10,001 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

Signature of SG